English  |  正體中文  |  简体中文  |  總筆數 :0  
造訪人次 :  52472400    線上人數 :  1129
教育部委託研究計畫      計畫執行:國立臺灣大學圖書館
 
臺灣學術機構典藏系統 (Taiwan Academic Institutional Repository, TAIR)
關於TAIR

瀏覽

消息

著作權

相關連結

"lin c c"的相關文件

回到依作者瀏覽
依題名排序 依日期排序

顯示項目 291-315 / 2549 (共102頁)
<< < 7 8 9 10 11 12 13 14 15 16 > >>
每頁顯示[10|25|50]項目

機構 日期 題名 作者
臺大學術典藏 2022-02-21T03:52:37Z Profile of the therascreen? EGFR RGQ PCR kit as a companion diagnostic for gefitinib in non-small cell lung cancer Hsiue E.H.-C.; JIH-HSIANG LEE; Lin C.-C.; Yang J.C.-H.
臺大學術典藏 2022-02-21T03:52:36Z Optimal management of EGFR-mutant non-small cell lung cancer with disease progression on first-line tyrosine kinase inhibitor therapy Liao B.-C.; Lin C.-C.; JIH-HSIANG LEE; Yang J.C.-H.
臺大學術典藏 2022-02-21T03:52:35Z Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: a genomic study Lin C.-C.; Shih J.-Y.; Yu C.-J.; Ho C.-C.; Liao W.-Y.; JIH-HSIANG LEE; Tsai T.-H.; Su K.-Y.; Hsieh M.-S.; Chang Y.-L.; Bai Y.-Y.; Huang D.D.-R.; Thress K.S.; Yang J.C.-H.
臺大學術典藏 2022-02-21T03:52:35Z Tumor PD-L1 expression and clinical outcomes in advanced-stage non-small cell lung cancer patients treated with nivolumab or pembrolizumab: Real-world data in Taiwan Lin S.-Y.; Yang C.-Y.; Liao B.-C.; Ho C.-C.; Liao W.-Y.; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Hsu W.-H.; Su K.-Y.; Chang Y.-L.; JIH-HSIANG LEE; Lin C.-C.; Shih J.-Y.; Yang J.C.; Yu C.-J.
臺大學術典藏 2022-02-21T03:52:34Z Best Response According to RECIST During First-line EGFR-TKI Treatment Predicts Survival in EGFR Mutation-positive Non�VSmall-cell Lung Cancer Patients Wu T.-H.; Hsiue E.H.-C.; JIH-HSIANG LEE; Lin C.-C.; Liao W.-Y.; Ho C.-C.; Shih J.-Y.; Yu C.-J.; Yang J.C.-H.
臺大學術典藏 2022-02-21T03:52:34Z Outcomes of research biopsies in clinical trials of EGFR mutation-positive non-small cell lung cancer patients pretreated with EGFR-tyrosine kinase inhibitors Liao B.-C.; Bai Y.-Y.; JIH-HSIANG LEE; Lin C.-C.; Lin S.-Y.; Lee Y.-F.; Ho C.-C.; Shih J.-Y.; Chang Y.-C.; Yu C.-J.; Chih-Hsin Yang J.; Yang P.-C.
臺大學術典藏 2022-02-21T03:52:32Z A phase I study of pexidartinib, a colony-stimulating factor 1 receptor inhibitor, in Asian patients with advanced solid tumors JIH-HSIANG LEE; Chen T.W.-W.; Hsu C.-H.; Yen Y.-H.; Yang J.C.-H.; Cheng A.-L.; Sasaki S.-I.; Chiu L.Y.; Sugihara M.; Ishizuka T.; Oguma T.; Tajima N.; Lin C.-C.
臺大學術典藏 2022-02-21T03:52:32Z Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors Yang C.-Y.; Liao W.-Y.; Ho C.-C.; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Su K.-Y.; Chang Y.-L.; Wu C.-T.; Hsu C.-C.; Liao B.-C.; Hsu W.-H.; JIH-HSIANG LEE; Lin C.-C.; Shih J.-Y.; Yang J.C.-H.; Yu C.-J.
臺大學術典藏 2022-02-21T03:52:31Z Two first-in-human studies of xentuzumab, a humanised insulin-like growth factor (IGF)-neutralising antibody, in patients with advanced solid tumours de Bono J.; Lin C.-C.; Chen L.-T.; Corral J.; Michalarea V.; Rihawi K.; Ong M.; JIH-HSIANG LEE; Hsu C.-H.; Yang J.C.-H.; Shiah H.-S.; Yen C.-J.; Anthoney A.; Jove M.; Buschke S.; Fuertig R.; Schmid U.; Goeldner R.-G.; Strelkowa N.; Huang D.C.-L.; Bogenrieder T.; Twelves C.; Cheng A.-L.
臺大學術典藏 2022-02-21T03:52:31Z Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving Crizotinib Yang C.-Y.; Liao W.-Y.; Ho C.-C.; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Liu Y.-N.; Su K.-Y.; Chang Y.-L.; Wu C.-T.; Liao B.-C.; Hsu C.-C.; Hsu W.-H.; JIH-HSIANG LEE; Lin C.-C.; Shih J.-Y.; Yang J.C.-H.; Yu C.-J.
臺大學術典藏 2022-02-21T03:52:30Z Serial Plasma Cell-Free Circulating Tumor DNA Tests Identify Genomic Alterations for Early Prediction of Osimertinib Treatment Outcome in EGFR T790M�VPositive NSCLC Liao B.-C.; Hsu W.-H.; JIH-HSIANG LEE; Yang C.-Y.; Tsai T.-H.; Liao W.-Y.; Ho C.-C.; Lin C.-C.; Shih J.-Y.; Yu C.-J.; Soo R.A.; Yang J.C.-H.
臺大學術典藏 2022-02-21T02:51:54Z Targeting CD38 and PD-1 with isatuximab plus cemiplimab in patients with advanced solid malignancies: Results from a phase I/II open-label, multicenter study Zucali P.A.; Lin C.-C.; Carthon B.C.; Bauer T.M.; Tucci M.; Italiano A.; Iacovelli R.; Su W.-C.; Massard C.; Saleh M.; Daniele G.; Greystoke A.; Gutierrez M.; Pant S.; YING-CHUN SHEN; Perrino M.; Meng R.; Abbadessa G.; Lee H.; Dong Y.; Chiron M.; Wang R.; Loumagne L.; L?pine L.; De Bono J.
臺大學術典藏 2022-02-21T02:04:36Z Prognostic value of PD-L1 expression on immune cells or tumor cells for locally advanced esophageal squamous cell carcinoma in patients treated with neoadjuvant chemoradiotherapy Huang T.-C.; Liang C.-W.; Li Y.-I.; Guo J.-C.; Lin C.-C.; Chen Y.-J.; ANN-LII CHENG; Hsu C.-H.
臺大學術典藏 2022-02-18T06:28:51Z Risk of colonoscopy-related complications in a fecal immunochemical test-based population colorectal cancer screening program WEN-FENG HSU; Chang C.-Y.; Chang C.-C.; Chang L.-C.; Chen C.-H.; Lin C.-C.; Lin Y.-M.; Lee C.-L.; Wu H.-Y.; Lee H.-C.; Lee Y.-C.; Su M.-Y.; Lin L.-J.; Chia S.-L.; Wu M.-S.; Chiu H.-M.
臺大學術典藏 2022-02-15T05:45:01Z Cutaneous presentation of disseminated cytomegalovirus infection in a non-transplant patient with hematological malignancy: A case report Yu H.-C.; Liu W.-D.; Kuo P.-H.; Lin C.-C.; UN-IN WU
臺大學術典藏 2022-02-14T07:10:40Z Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving Crizotinib Yang C.-Y.; Liao W.-Y.; Ho C.-C.; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Liu Y.-N.; Su K.-Y.; YIH-LEONG CHANG; Wu C.-T.; Liao B.-C.; Hsu C.-C.; Hsu W.-H.; Lee J.-H.; Lin C.-C.; Shih J.-Y.; Yang J.C.-H.; Yu C.-J.
臺大學術典藏 2022-02-14T05:27:17Z Endoscopic ultrasound ablation in a patient with multiple metastatic pancreatic tumors from adrenocorticotropic hormone-producing thymic neuroendocrine neoplasm Chang L.-K.; Chen K.-C.; Cheng M.-F.; Lin C.-C.; HSIU-PO WANG; Sung C.-T.; Chen J.-H.; Yen R.-F.; Hsu C.-L.; Shih S.-R.
臺大學術典藏 2022-02-07T07:49:00Z Polatuzumab vedotin�Vbased salvage immunochemotherapy as third-line or beyond treatment for patients with diffuse large B-cell lymphoma: a real-world experience Wang Y.-W.; Tsai X.C.-H.; Hou H.-A.; Tien F.-M.; Liu J.-H.; Chou W.-C.; Ko B.-S.; Chen Y.-W.; Lin C.-C.; Cheng C.-L.; Lo M.-Y.; Lin Y.-C.; Lu L.-C.; Wu S.-J.; SUNG-HSIN KUO; Hong R.-L.; Huang T.-C.; Yao M.
臺大學術典藏 2022-02-07T03:29:06Z Prognostic value of PD-L1 expression on immune cells or tumor cells for locally advanced esophageal squamous cell carcinoma in patients treated with neoadjuvant chemoradiotherapy Huang T.-C.; Liang C.-W.; Li Y.-I.; Guo J.-C.; Lin C.-C.; Chen Y.-J.; Cheng A.-L.; CHIH-HUNG HSU
臺大學術典藏 2022-02-07T03:29:04Z Response to Immune Checkpoint Inhibitors in Recurrent or Metastatic Esophageal Squamous Cell Carcinoma May Be Affected by Tumor Sites Guo J.-C.; Lin C.-Y.; Lin C.-C.; Huang T.-C.; Lien M.-Y.; Lu L.-C.; Kuo H.-Y.; CHIH-HUNG HSU
臺大學術典藏 2022-01-25T07:24:22Z Risk of colonoscopy-related complications in a fecal immunochemical test-based population colorectal cancer screening program Hsu W.-F.; Chang C.-Y.; Chang C.-C.; Chang L.-C.; Chen C.-H.; Lin C.-C.; Lin Y.-M.; Lee C.-L.; Wu H.-Y.; Lee H.-C.; Lee Y.-C.; Su M.-Y.; Lin L.-J.; Chia S.-L.; MING-SHIANG WU; Chiu H.-M.
臺大學術典藏 2022-01-25T05:07:25Z Androgen pathway stimulates MicroRNA-216a transcription to suppress the tumor suppressor in lung cancer-1 gene in early hepatocarcinogenesis Chen P.-J.; Yeh S.-H.; Liu W.-H.; Lin C.-C.; Huang H.-C.; CHI-LING CHEN; Chen D.-S.; Chen P.-J.
臺大學術典藏 2022-01-25T03:25:12Z Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients Su T.-H.; Hu T.-H.; Chen C.-Y.; Huang Y.-H.; Chuang W.-L.; Lin C.-C.; Wang C.-C.; Su W.-W.; Chen M.-Y.; Peng C.-Y.; Chien R.-N.; Huang Y.-W.; Wang H.-Y.; Lin C.-L.; Yang S.-S.; Chen T.-M.; Mo L.-R.; Hsu S.-J.; Tseng K.-C.; Hsieh T.-Y.; Suk F.-M.; Hu C.-T.; Bair M.-J.; Liang C.-C.; Lei Y.-C.; Tseng T.-C.; CHI-LING CHEN; Kao J.-H.; the C-TEAM study group; the Taiwan Liver Diseases Consortium
臺大學術典藏 2022-01-24T09:31:34Z Efficacy of maternal tenofovir disoproxil fumarate in interrupting mother-to-infant transmission of hepatitis B virus Chen H.-L.; Lee C.-N.; Chang C.-H.; Ni Y.-H.; Shyu M.-K.; Chen S.-M.; Hu J.-J.; Lin H.H.; Zhao L.-L.; Mu S.-C.; Lai M.-W.; Lee C.-L.; Lin H.-M.; Tsai M.-S.; Hsu J.-J.; Chen D.-S.; Chan K.A.; Chang M.-H.; Su Y.-N.; Shih J.-C.; Chao K.-H.; Wu J.-F.; Hsu H.-Y.; CHUN-JEN LIU; Su T.-H.; Lin C.-C.; Lin P.-Y.; Yang W.-R.; Yang C.-K.; Chang Y.-K.; Chen K.-H.; Lin Y.-H.; Chen H.-J.; Pan H.-S.; Lau B.-H.; Cheng P.-J.; Chang Y.-L.; Chiueh H.-Y.; Wang T.-H.; Lo L.-M.; Hsieh C.-L.; Cheng S.-W.; Lin L.-H.; She B.-Q.; Koh K.-J.; Hung Y.-L.; Peng F.-S.; Lin Y.-C.; Wu T.-C.; Chen C.-Y.; Chen C.-P.; Huang J.-P.; Yeung C.-Y.; Lin C.-J.; Chiu W.-T.; Wang D.-S.; Lin W.-T.; Hwang K.-S.; Huang C.-F.; Taiwan Study Group for the Prevention of Mother-to-Infant Transmission of HBV (PreMIT Study)
臺大學術典藏 2022-01-24T09:31:13Z Decreased neonatal hepatitis B virus (HBV) viremia by maternal tenofovir treatment predicts reduced chronic HBV infection in children born to highly viremic mothers Chang K.-C.; Chang M.-H.; Lee C.-N.; Chang C.-H.; Wu J.-F.; Ni Y.-H.; Wen W.-H.; Shyu M.-K.; Lai M.-W.; Chen S.-M.; Hu J.-J.; Lin H.H.; Hsu J.-J.; Mu S.-C.; Lin Y.-C.; CHUN-JEN LIU; Chen D.-S.; Lin L.-H.; Chen H.-L.; Hwa H.-L.; Su Y.-N.; Shih J.-C.; Chao K.-H.; Hsu H.-Y.; Chiu Y.-C.; Su T.-H.; Lin C.-C.; Lin P.-Y.; Yang W.-R.; Zhao L.-L.; Yang C.-K.; Chang Y.-K.; Chen K.-H.; Lin Y.-H.; Chen H.-J.; Pan H.-S.; Lau B.-H.; Lee C.-L.; Cheng P.-J.; Chang Y.-L.; Chiueh H.-Y.; Wang T.-H.; Lo L.-M.; Hsieh C.-L.; Cheng S.-W.; Tsai M.-S.; She B.-Q.; Koh K.-J.; Hung Y.-L.; Lin H.-M.; Peng F.-S.; Wu T.-C.; Chen C.-Y.; Chen C.-P.; Huang J.-P.; Yeung C.-Y.; Lin C.-J.; Chiu W.-T.; Wang D.-S.; Lin W.-T.; Hwang K.-S.; Huang C.-F.; The Taiwan Study Group for the Prevention of Mother-to-Infant Transmission of HBV (PreMIT study)

顯示項目 291-315 / 2549 (共102頁)
<< < 7 8 9 10 11 12 13 14 15 16 > >>
每頁顯示[10|25|50]項目